C07K 14/525
Tumour necrosis factor [tnf]
Official title: Tumour necrosis factor [TNF]
C07K14/525 (Tumour necrosis factor [tnf]) appears on 707 US grants and 1,014 published applications in this corpus.
Search patents in C07K- Granted patents
- 707
- Published applications
- 1,014
- Assignees
- 442
- Inventors
- 1,670
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 0 | 0 |
| 1987 | 6 | 0 |
| 1988 | 4 | 0 |
| 1989 | 6 | 0 |
| 1990 | 6 | 0 |
| 1991 | 8 | 0 |
| 1992 | 8 | 0 |
| 1993 | 8 | 0 |
| 1994 | 4 | 0 |
| 1995 | 7 | 0 |
| 1996 | 9 | 0 |
| 1997 | 21 | 0 |
| 1998 | 18 | 0 |
| 1999 | 17 | 0 |
| 2000 | 7 | 0 |
| 2001 | 11 | 6 |
| 2002 | 8 | 35 |
| 2003 | 18 | 47 |
| 2004 | 8 | 34 |
| 2005 | 4 | 36 |
| 2006 | 30 | 40 |
| 2007 | 37 | 33 |
| 2008 | 21 | 32 |
| 2009 | 19 | 25 |
| 2010 | 21 | 26 |
| 2011 | 14 | 23 |
| 2012 | 13 | 29 |
| 2013 | 17 | 43 |
| 2014 | 23 | 62 |
| 2015 | 37 | 55 |
| 2016 | 35 | 46 |
| 2017 | 28 | 44 |
| 2018 | 27 | 55 |
| 2019 | 28 | 38 |
| 2020 | 34 | 49 |
| 2021 | 29 | 44 |
| 2022 | 25 | 44 |
| 2023 | 23 | 55 |
| 2024 | 23 | 45 |
| 2025 | 26 | 35 |
| 2026 | 15 | 33 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- TNFR2 agonists with improved stability15 Sep 2026US 12,735,472 B2Universität Stuttgart
- Tumor necrosis factor (TNF) receptor superfamily (TNFRSF) receptor-activating antibody fusion proteins with FCγR-independent agonistic activity (TNFRSF receptor-activating antibody fusion proteins with FCγR-independent agonistic activity; TRAAFFIAA)25 Aug 2026US 12,715,928 B2Julius-Maximilians-UniversitäT WüRzburg
- Heterodimeric human IgG1 polypeptides with isoelectric point modifications23 Jun 2026US 12,662,553 B2Xencor, Inc.
- Combination therapy using a chimeric antigen receptor16 Jun 2026US 12,653,850 B2Novartis AG
- Multitransgenic pigs comprising ten genetic modifications for xenotransplantation9 Jun 2026US 12,648,548 B2Revivicor, Inc.
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Engineered t cells3 Sep 2026US 2026/0258104 A1Intellia Therapeutics, Inc.
- Fibroblast binding agents and use thereof20 Aug 2026US 2026/0240942 A1Orionis Biosciences BV
- Methods for the production of dendritic cells by modulating retinoid signaling6 Aug 2026US 2026/0226411 A1FUJIFILM Holdings America Corporation
- Cell capable of being differentiated into m2 macrophage in tumor tissue and having property such that m2 macrophage differentiated from said cell express inflammatory cytokine, and composition containing said cell6 Aug 2026US 2026/0226412 A1Kyushu University, National University Corporation
Most cited
By later US patents
- Gene therapy759US 5,399,346 AThe United States of America as represented by the Department of Health and Human Services · 1995
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Modified peptides as therapeutic agents359US 6,660,843 B1Amgen Inc. · 2003
- Cysteine-depleted muteins of biologically active proteins280US 4,959,314 ACetus Corporation · 1990
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014